Who are ibandronate, calcium and vitamin D's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibandronate-calcium-and-vitamin-d.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ibandronate, calcium and vitamin D — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ibandronate, calcium and vitamin D (ibandronate, calcium and vitamin D) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate combination therapy. Area: Bone metabolism / Osteoporosis.

marketed Bisphosphonate combination therapy Farnesyl pyrophosphate synthase (ibandronate); calcium-sensing receptor and vitamin D receptor (supportive agents) Bone metabolism / Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

ibandronate, calcium and vitamin D (ibandronate, calcium and vitamin D) — Charite University, Berlin, Germany. Ibandronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase, while calcium and vitamin D support bone mineralization and calcium homeostasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ibandronate, calcium and vitamin D TARGET	ibandronate, calcium and vitamin D	Charite University, Berlin, Germany	marketed	Bisphosphonate combination therapy	Farnesyl pyrophosphate synthase (ibandronate); calcium-sensing receptor and vitamin D receptor (supportive agents)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate combination therapy class)

Charite University, Berlin, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ibandronate, calcium and vitamin D — Competitive Intelligence Brief. https://druglandscape.com/ci/ibandronate-calcium-and-vitamin-d. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab